| scholarly article | Q13442814 |
| P356 | DOI | 10.1021/JM00316A033 |
| P953 | full work available at URL | https://pubs.acs.org/doi/pdf/10.1021/jm00316a033 |
| P698 | PubMed publication ID | 6037060 |
| P2093 | author name string | J. A. Montgomery | |
| R. James | |||
| G. S. McCaleb | |||
| T. P. Johnston | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | molecular medicine | Q3523816 |
| P304 | page(s) | 668-674 | |
| P577 | publication date | 1967-07-01 | |
| P1433 | published in | Journal of Medicinal Chemistry | Q900316 |
| P1476 | title | The modes of decomposition of 1,3-bis(2-chloroethyl)-1-nitrosourea and related compounds | |
| The Modes of Decomposition of 1,3-Bis(2-chloroethyl)-1-nitrosourea and Related Compounds | |||
| P478 | volume | 10 |
| Q39919334 | 1,3-Bis(2-Chloroethyl)-1-Nitrosourea (Bcnu) And Other Nitrosoureas In Cancer Treatment: A Review |
| Q41654326 | Alkalosis monitored by31P NMR in a human glioma cell line exposed to the anti-tumor drug 1, 3-bis (2-chloroethyl)-1-nitrosourea |
| Q43169766 | Alkylation and Carbamylation Effects of Lomustine and Its Major Metabolites and MGMT Expression in Canine Cells |
| Q47945973 | Anti-sickling activity of nitrosoureas |
| Q39668908 | Cancer, clinical pharmacology, and aging. |
| Q68205561 | Chemical stability of ecomustine, a new antitumor agent in aqueous and biological media as assessed by high-performance liquid chromatography |
| Q35992207 | Chemopotentiation of CCNU metabolites by misonidazole |
| Q40252831 | Chloroethylnitrosourea cancer chemotherapeutic agents |
| Q37042746 | Chlorozotocin. Mechanism of reduced bone marrow toxicity in mice |
| Q42807419 | Clinical activity of laromustine (Onrigin™) in hematologic malignancies |
| Q43806325 | Comparison of the effects of cysteine upon the decomposition of nitrosoureas and of 1-methyl-3-nitro-1-nitrosoguanidine |
| Q39749041 | DNA adducts and DNA damage by antineoplastic and carcinogenic N-nitrosocompounds |
| Q39161154 | Degradation of Carmustine in Aqueous Media |
| Q70058392 | Differential distribution and covalent binding of two labeled forms of methyl-CCNU in the Fischer 344 rat |
| Q48864401 | Distribution of 13N in rat tissues following intravenous administration of nitroso-labeled BCNU. |
| Q66964381 | Effect of BCNU on glutathione metabolism in human blood cells |
| Q39689652 | Effects of carbamoylating agents on tumor metabolism. |
| Q35991428 | Enhancement of nitrosourea cytotoxicity by misonidazole in vitro: correlation with carbamoylating potential |
| Q67003178 | Evaluation of the alkylating activity of nitrosoureas by thin-layer densitometry |
| Q43566518 | Evaluation of the role of isocyanates in the action of therapeutic nitrosoureas |
| Q40941757 | Inactivation of glutathione reductase by 2-chloroethyl nitrosourea-derived isocyanates |
| Q46316730 | Increased degradation rate of nitrososureas in media containing carbonate |
| Q39219217 | Mechanism of Hydrolysis of Halogenated Nitrosoureas |
| Q48544494 | Pharmacokinetics of 11C-BCNU in experimental brain tumor |
| Q41703583 | Pharmacokinetics of fotemustine and BCNU in plasma, liver and tumor tissue of rats bearing two lines of Walker 256 carcinoma. |
| Q39993380 | Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro |
| Q70111920 | Preparative and analytical high-performance liquid chromatographic methods in the synthesis and analysis of decomposition of nitrosourea nucleosides |
| Q37242777 | Prophage Induction in Lysogenic Escherichia coli with N -Nitroso Compounds and Derivatives |
| Q44768385 | Rationale for Design of Biologically Reversible Drug Derivatives: Prodrugs |
| Q48220778 | Relationship of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) pharmacokinetics of uptake, distribution, and tissue/plasma partitioning in rat organs and intracerebral tumors |
| Q34661209 | Results of in vitro and in vivo genetic toxicity tests on methyl isocyanate |
| Q28319593 | Some new congeners of the anticancer agent 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) synthesis of bifunctional analogs and water soluble derivatives and preliminary evaluation of their chemotherapeutic potential |
| Q39814611 | Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. General considerations, the nitrosoureas and alkylating agents |
| Q67364906 | Studies of the mechanism of action of the tumour-inhibitory nitrosoureas |
| Q69539148 | Synthesis and Anticancer Activity of 5-(Propargyloxymethyl)-2-oxazolidinones |
| Q36041291 | The binding of 14C labelled 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) to macromolecules of sensitive and resistant tumours |
| Q68485012 | The hepatotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in rats. Ultrastructural evidence of a delayed microtubular toxicity |
| Q33471442 | Treatment of Advanced Hodgkin’s Disease with [1,3 Bis (2-Chloroethyl)-1-Nitrosourea] BCNU |
| Q36344695 | Tumor cell anti-oxidant defenses. Inhibition of the glutathione redox cycle enhances macrophage-mediated cytolysis |
| Q43654338 | Two glycine containing 2-chloroethylnitrosoureas--a comparative study on some physicochemical properties, in vivo antimelanomic effects and immunomodulatory properties |
| Q30428760 | Understanding and manipulating O6-methylguanine-DNA methyltransferase expression |
Search more.